Is Radiotherapy Adequate Treatment for Patients not in Complete Metabolic Response after First-Line Chemotherapy for DLBCL?

被引：0
|
作者：
Brady, J. L. [1 ]
Mikhaeel, G. [2 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust London, London, England
[2] Kings Coll London, Canc Div, London, England
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2019年 / 105卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2019.06.518
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
139
引用
收藏
页码：S68 / S68
页数：1
相关论文
共 50 条
  • [31] Tislelizumab plus chemotherapy as first-line treatment for lung cancer in Chinese patients
    Wang, Z.
    Zhao, J.
    Ma, Z.
    Cui, J.
    Shu, Y.
    Liu, Z.
    Cheng, Y.
    Leaw, S.
    Wu, Y.
    Ma, Y.
    Tan, W.
    Wang, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1444 - S1444
  • [32] First-line treatment in young patients
    San Miguel, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S19 - S19
  • [33] First-line treatment in elderly patients
    Montefusco, V.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S19 - S19
  • [34] Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment - Prognostic factors
    Brun, B
    Benchalal, M
    Lebas, C
    Piedbois, P
    Lin, M
    Lebourgeois, JP
    CANCER, 1997, 79 (11) : 2137 - 2146
  • [35] Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy
    Mayerhofer, K
    Kucera, E
    Zeisler, H
    Speiser, P
    Reinthaller, A
    Sevelda, P
    GYNECOLOGIC ONCOLOGY, 1997, 64 (01) : 109 - 113
  • [36] Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib
    da Fonseca, Leonardo Gomes
    Marta, Guilherme Nader
    Freitas Melro Braghiroli, Maria Ignez
    Chagas, Aline Lopes
    Carrilho, Flair Jose
    Hoff, Paulo Marcelo
    Sabbaga, Jorge
    BMC CANCER, 2018, 18
  • [37] Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib
    Leonardo Gomes da Fonseca
    Guilherme Nader Marta
    Maria Ignez Freitas Melro Braghiroli
    Aline Lopes Chagas
    Flair Jose Carrilho
    Paulo Marcelo Hoff
    Jorge Sabbaga
    BMC Cancer, 18
  • [38] The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy
    Ikeda, Go
    Yamamoto, Shun
    Kato, Ken
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (01) : 55 - 65
  • [39] ctDNA-based Tumor Kinetics correlates with Treatment Response after Combination of Tafasitamab with R-CHOP with and without Lenalidomide in Patients with First-line Therapy in DLBCL
    Khouja, M.
    Schilhabel, A.
    Kotrova, M.
    Brueggemann, M.
    Kuffer, C.
    Blair, D.
    Darzentas, N.
    Pott, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 254 - 255
  • [40] Biomarker testing to guide first-line PARP inhibitor maintenance for patients with advanced ovarian cancer after response to first-line platinum chemotherapy: A cost-effectiveness study
    Fan, Lin
    Elsea, David
    Muston, Dominic
    Mihai, Adela
    Monberg, Matthew
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S195 - S195
12345